NCT03082534 — University of California, San Diego cancer immunotherapy trial
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Registry record
| Registry ID | NCT03082534 ↗ |
|---|---|
| Lead sponsor | University of California, San Diego |
| Collaborators | Merck Sharp & Dohme LLC |
| Phase | Phase 2 |
| Status | Completed |
| Indication | HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Nasopharynx Cancer, Sinonasal Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma |
| Enrollment | 78 participants |
| Start date | 2017-03-28 |
| Primary completion | 2025-07-21 |
| Last registry update | 28 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03082534), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT03082534?
NCT03082534 (Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma) is registered on ClinicalTrials.gov as Phase 2, sponsored by University of California, San Diego.
Is NCT03082534 recruiting?
As of the 2026-01-28 registry update, NCT03082534 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03082534?
The lead sponsor is University of California, San Diego. Collaborators: Merck Sharp & Dohme LLC.
What condition does NCT03082534 study?
The registered conditions are HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Nasopharynx Cancer, Sinonasal Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma. Primary completion is listed as 2025-07-21.
Are results available for NCT03082534?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03082534.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.